News

Public · Published

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Pharming Group reported third quarter 2026 total revenues of US$117.6 million, up 21% from a year earlier. Operating profit rose 89% to US$29.9 million, and the company tightened its 2026 total revenue guidance to US$380 million to US$390 million.

Published:

Updated:

What happened

Pharming Group reported third quarter 2026 total revenues of US$117.6 million, up 21% from a year earlier. Operating profit rose 89% to US$29.9 million, and the company tightened its 2026 total revenue guidance to US$380 million to US$390 million.

Confirmed

Global impact / market context

Higher revenue and operating profit mean Pharming keeps more cash from each sale, which funds launches and clinical trials without relying on borrowed money. Tightened guidance signals management has a narrower view of expected full-year sales, which can change how investors judge future cash generation.

Analyst inference

Revenue beat market expectations, with RUCONEST sales up 14% on demand stabilization and seasonal inventory increases, and Joenja sales up 58% on U.S. and international demand. Cash from operations reached US$32.4 million this quarter, lifting the cash position to US$190.9 million, which supports launch spending.

Analyst inference

What to watch

  1. Pharming expects Phase II topline data for leniolisib in a broader CVID patient population in November 2026; CVID is a genetic immune disorder, so results could shape whether the drug's label expands. Confirmed
  2. Watch whether Pharming advances the U.S. pediatric label and the Germany and Japan launches for Joenja, since each launch adds selling costs before it adds revenue, which affects near-term profit per sale. Proposed
  3. Track whether tightened 2026 revenue guidance of US$380 million to US$390 million is met, since falling short would weaken the case that RUCONEST demand has stabilized and that Joenja growth is durable. Analyst inference

Evidence

  • Original source link unavailable